FGFR1 and lymphoid neoplasm: The mOS of 21.1 months (95% CI, 14.8-NE) in the FGFR2 fusion/rearrangement group was significantly longer than the FGF/FGFR alteration group (mOS 6.7; 95% CI, 2.1-10.6).32 Similarly, the phase 2 FIGHT-203 trial evaluated the efficacy of pemigatinib in myeloid and lymphoid neoplasms with FGFR1 rearrangements (N = 33).